Skip to content

Characteristics and Treatment Outcome of Liver Abscesses: An Observational Study

Characteristics and Treatment Outcome of Liver Abscesses: An Observational Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06852235
Enrollment
70
Registered
2025-02-28
Start date
2025-03-15
Completion date
2027-06-01
Last updated
2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Abscess

Brief summary

1. To assess the frequency, clinical presentation, microbiological and radiological characteristics of liver abscesses. 2. To evaluate the management plan and treatment outcome of liver abscess. 3. To study risk factors of liver abscess.

Detailed description

There is a paucity of information on liver abscesses' epidemiology and characteristics in the Middle East in general and Egypt in particular. The incidence of liver abscess varies from one country to another. The annual incidence of pyogenic liver abscess has been estimated at 2.3 cases per 100,000 populations and 18-20 per 100 000 hospital admissions (Mohsen et al 2002, Kaplan et al 2004). Liver abscess is a potentially life-threatening condition (Ahmed et al., 2016). A review by Chan KS et al. of 16 pyogenic LA (PLA) articles showed mortality rates ranging from 0% to 15.7 % (Chan et al., 2022). The etiology of LA can be bacterial (most often polymicrobial), parasitic (amebic essentially), mixed (pyogenic superinfection of parasitic abscess) or more rarely fungal (Nakanishi et al., 2009). Microbes can invade the liver parenchyma by way of the bile ducts, blood stream (hematogenic, most often portal), or by contiguous spread, especially via the gallbladder bed (Yoo et al., 1993, Thomsen et al., 2007). Advanced age, diabetes mellitus (DM) and the presence of underlying malignancy are considered major risk factors, and the latter is associated with a worse prognosis (Yoo et al., 1993, Thomsen et al., 2007). The number of cryptogenic liver abscess cases has been on the rise, and no predisposing conditions (cryptogenic) was reported in 18% (McNeil et al. 2020). The diagnosis of LA relies essentially on imaging. Sonography and CT scan lead to diagnosis in more than 90% of cases (Halvorsen et al., 1984).

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Diagnosis of LA will be based on typical appearance on ultrasound (US) or computed tomography (CT) of abdomen with clinical features consistent with the diagnosis (fever, chills, jaundice, right upper quadrant pain/epigastric discomfort). * US or CT-guided aspiration of pus from a hepatic lesion. * Complete resolution of radiological abnormalities following antimicrobial therapy.

Exclusion criteria

* Liver abscess that occurs secondary to hydatid cyst. * Liver abscess associated with underlying malignancy. * Patient with incomplete medical records.

Design outcomes

Primary

MeasureTime frameDescription
1. To assess the frequency, clinical picture, microbiological and radiological characteristics of liver abscesses.BaselineData will be statistically evaluated by SPSS version 22. Numerical data will be expressed as means ± SDs. Categorical data will be expressed as frequencies (percentages). Comparison between groups will be conducted using t-test or Chi square test as appropriate. P value \<0.05 will be considered as significant.

Secondary

MeasureTime frameDescription
2. To evaluate the management plan and treatment outcome of liver abscess.BaselineData will be statistically evaluated by SPSS version 22. Numerical data will be expressed as means ± SDs. Categorical data will be expressed as frequencies (percentages). Comparison between groups will be conducted using t-test or Chi square test as appropriate. P value \<0.05 will be considered as significant.
3. To study risk factors of liver abscess.BaselineData will be statistically evaluated by SPSS version 22. Numerical data will be expressed as means ± SDs. Categorical data will be expressed as frequencies (percentages). Comparison between groups will be conducted using t-test or Chi square test as appropriate. P value \<0.05 will be considered as significant.

Contacts

Primary ContactMarco Magdy, Bachelor
marcomagdy1997@gmail.com01270777143

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026